BACKGROUND: Routine monitoring of cancer-related distress is recognized as essential to quality care and mandated by a major accrediting organization. However, to the authors' knowledge, few cancer-specific measures have been developed to date to assess the multiple cancer-related factors contributing to this distress. In the current study, the authors examined the psychometric properties of the Cancer and Treatment Distress (CTXD) measure over time in hematopoietic cell transplantation (HCT) recipients. METHODS: As a secondary analysis of a multicenter randomized controlled clinical trial, adult patients undergoing autologous or allogeneic HCT completed patient-reported outcomes including the CTXD and the Medical Outcomes Study Short Form-36 (SF-36) before transplantation and 100 days and 180 days after HCT. RESULTS: Across 21 transplantation centers, a total of 701 patients consented, underwent transplantation, and were included in the current analyses, 645 of whom were alive at 100 days and 618 of whom were alive at 180 days. Internal consistency reliability was found to be strong for the overall CTXD at the 3 time points: Cronbach alphas (a) were .94, .95, and .95, respectively. Subscale reliability met hypothesized levels of an a>.70 across time, with the lowest reliability noted for the Identity subscale at 180 days (a 5 .77). Correlations with the SF-36 Mental Health subscale were higher than with the Physical Functioning subscale at each time point, thereby supporting convergent and discriminant validity. Strong correlations of the pretransplantation CTXD with the posttransplantation CTXD and SF-36 Mental Health subscale supported predictive validity. CONCLUSIONS: The CTXD is reliable and valid as a measure of cancer distress both before and after HCT. It may be a useful tool for measuring dimensions of distress and for defining those patients requiring treatment for distress during and after transplantation.
INTRODUCTION
Emotional distress related to the diagnosis and treatment of cancer impacts quality of life for many patients with cancer and is now widely accepted as a symptom that requires routine assessment. 1 The National Comprehensive Cancer Network has provided distress screening guidelines to assist clinicians since 1999. 2, 3 More recently, the American College of Surgeons Commission on Cancer has mandated psychosocial distress screening for accredited cancer programs. 4 Uncertainty and fear of disease recurrence are widely recognized as major sources of stress during cancer treatment, along with other demands such as physical changes, financial strain, and managing medical needs. However, these domains are not included in the majority of measures of distress or in standardized health-related quality of life measures. Although it is important to evaluate the overall distress level, it also is important to identify those factors contributing to distress to target appropriate interventions. For example, a patient with distress due to family or financial concerns may benefit from couples-based or financial counseling, whereas a patient struggling mainly with uncertainty, fear of disease recurrence, or depression may benefit from individual therapy, including medication evaluation.
Despite recognition that distress is important to measure, to the best of our knowledge few tools have been developed to date to assess the multiple sources of cancer-related distress and even fewer have had their psychometric properties over time evaluated. Measures such as the single-item Distress Thermometer have been used over the course of treatment, with distress noted to decrease from pretreatment to the end of chemotherapy. 5, 6 Although the Distress Thermometer is an attractive measure because of its brevity, it may not be ideal when evaluating response to treatment or when determining the sources of distress in regard to needs for clinical care. We developed the Cancer and Treatment Distress (CTXD) measure to assess not only an overall level of distress but also to evaluate cancer-related factors contributing to distress. 7 These factors, which are subscales of the CTXD, include uncertainty, family strain, health burden, finances, loss of identity, and medical demands. Previous work has confirmed the reliability and validity of the CTXD in a multisite cohort of hematopoietic cell transplantation (HCT) recipients before transplantation. 7 However, the psychometric properties of the CTXD after transplantation have not been examined to date.
Recipients of HCT undergo demanding treatment, with a higher risk of acute toxicities and late effects than patients with cancer who receive many other treatments. [8] [9] [10] [11] To the best of our knowledge, their related distress has not been well characterized, but may differ from that of patients with other cancers given the intensity of treatment and the uncertainty of long-term complications. In research comparing survivors of HCT with survivors in the Childhood Cancer Survivor Study, the survivors of HCT demonstrated elevated risks of severe/life-threatening conditions and functional impairments. 8 They also were found to have a 9-fold increased risk of late mortality, [12] [13] [14] and to be at risk of poorer psychosocial health, with more depression and posttraumatic stress symptoms than age-matched norms. [15] [16] [17] Distress in survivors of HCT continues over a lengthy period, extending well beyond their physical recovery. 15 To facilitate addressing the psychological needs of survivors of HCT, there is value in establishing the psychometric reliability, validity, and stability of the CTXD in posttreatment survivors of HCT.
This secondary analysis had 3 aims: 1) to replicate previous findings of acceptable internal consistency of the CTXD before transplantation; 2) to determine whether the CTXD exhibits acceptable internal consistency after transplantation at 100 days and 180 days; and 3) to assess the convergent, discriminant, and predictive validity of the CTXD using a standardized measure of physical and mental health. For acceptable reliability, we required that the internal consistency of the CTXD as measured by the Cronbach a be > .80 for the total mean score and >.70 for the subscales at each time point. To establish acceptable construct validity, we required that at each time point the CTXD total score correlate by >0.50 with the Medical Outcomes Study Short Form-36 (SF-36) Mental Health (MH) subscale for convergent validity and correlate by <0.50 with the SF-36 Physical Functioning (PF) subscale for discriminant validity. For predictive validity, we required the pretransplantation CTXD total score to have large-magnitude correlations (correlation coefficient [r] > 0.50) with posttransplantation CTXD scores and at least moderate negative correlation (r < -0.30) with posttransplantation MH scores.
MATERIALS AND METHODS

Participants
Patients were recruited for a multicenter randomized controlled trial (RCT) examining the effects of a stress management and exercise program on quality of life in patients undergoing autologous or allogeneic HCT (the Blood and Marrow Transplant Clinical Trials Network [BMT CTN] 0902 study; ClinicalTrials.gov identifier NCT01278927). The RCT did not demonstrate differences between the intervention and control groups. 18 Participants were recruited from 21 centers in the United States. Eligible patients were: 1) aged 18 years; 2) able to speak and read English; 3) able to exercise at low to moderate intensity as determined by their physician and self-reported judgment; and 4) preparing to undergo autologous or allogeneic transplantation within 6 weeks. Patients were excluded if they: 1) had issues that prevented safe ambulation; 2) were participating in another clinical trial with quality of life or functional status as a primary endpoint; 3) were planning to receive anticytotoxic therapies other than tyrosine kinase inhibitors; 4) were planning to receive a donor lymphocyte infusion within 100 days of transplantation; or 5) were planning to receive tandem transplantation (ie, a planned autologous/autologous or autologous/allogeneic HCT).
Procedure
All study procedures were approved by the protocol review committee established by the National Heart, Lung, and Blood Institute in addition to each institution's Institutional Review Board. Eligibility was determined via chart review and in consultation with the attending physician. Eligible patients were recruited and informed consent was provided by each participant before the day of graft infusion (ie, day 0). After informed consent was obtained, participants completed the baseline assessment before randomization. 18 Participants completed followup assessments at 100 days and 180 days after HCT.
Measures
Demographic and clinical data
Demographic data obtained before HCT included age, sex, race, ethnicity, marital status, education, and income.
Clinical data were collected via BMT CTN reporting and included disease type, transplantation type, pre-HCT Karnofsky performance score, and survival at 100 days and 180 days after HCT.
Cancer-related distress
The CTXD measures cancer-related distress over the past week. 7 Items were generated initially based on qualitative interviews with patients asking what aspects of their diagnosis and treatment were most distressing to them. Physicians, nurses, and other health care providers then reviewed the items and generated additional content. Additional interviews with patients and factor analyses were used to refine the item pool, resulting in a 22-item measure comprised of a total mean score and 6 subscales: Uncertainty ("not knowing what the future will bring"), Health Burden ("not being able to do what I used to do"), Family Strain ("wondering about the emotional toll on my family or other caregivers"), Identity ("changes in my appearance"), Finances ("cost of treatment"), and Medical Demands ("dealing with the medical system"). Response options are on a 4-point scale from 0 (indicating "none") to 3 (indicating "severe"). Scores are the mean response across the scale/subscale items. Higher scores indicate greater distress.
Quality of life
The acute (1-week) version of the SF-36 was used to assess health-related quality of life. 19 The PF and MH subscales were used to assess convergent and divergent validity, respectively. Published scoring procedures were followed, producing scores on these subscales that ranged from 0 to 100, with higher scores reflecting a better quality of life. The other 6 SF-36 subscales were deemed less relevant for validity testing. The often-used physical component and mental component summaries were not used because the summaries include a weighted contribution from each of the SF-36 subscales, potentially confounding the 2 summary scores when used for validity testing. 20 
Statistical Analyses
To examine changes in internal consistency across time, the Cronbach a was calculated for the total mean CTXD score and the 6 subscales at each time point. We used Pearson correlations to examine convergent and divergent validity of the CTXD with the SF-36 MH and PF subscales, respectively, at each time point. The Cohen criterion was used to interpret the magnitude of r (an r < 0.3 indicates small magnitude; an r > 0.3 and <0.5 indicates moderate magnitude; and an r > 0.5 indicates large/ strong magnitude). 21 Analyses were completed with SAS statistical software (version 9.3; SAS Institute Inc, Cary, NC).
RESULTS
Participants
With regard to sociodemographic characteristics (Table 1) , the majority of participants were male (57%) with an average age of 54.6 years (standard deviation [SD], 12.8 years) but with a broad age range from 18 to 75 years, and were largely white (88%) and non-Hispanic/Latino (93%), which is consistent with the HCT population. The cohort was well educated, with 80% of participants having more than a high school education, and most were married or living with a partner (74%).
With regard to clinical characteristics (Table 2) , approximately one-half of the cohort received autologous HCT with the remaining participants evenly split between myeloablative (25%) and nonmyeloablative (25%) allogeneic transplantations. Diagnoses were diverse, with multiple myeloma being the most common (27%). Of the 701 participants, 645 were alive to complete the 100-day assessment, and 618 were alive to complete the 180-day assessment. All participants completed the CTXD at least once and were included in the analyses; 2 participants did not complete the baseline CTXD (0.3%); and, of the survivors, 79 (12%) and 125 (20%), respectively, did not complete the CTXD at 100 days and 180 days. Among those who were alive, baseline CTXD scores did not differ between respondents versus nonrespondents at 100 days and 180 days or when tested for interactions of responder status with the sociodemographic and clinical variables listed in Tables 1 and 2 .
Internal Consistency Table 3 presents means, SDs, and Cronbach a values for the entire scale and for the 6 subscales at each time point. The full CTXD met requirements for internal consistency over time with an a .94. Each of the 6 subscales exceeded the criterion level of >0.70 at each time point, which was considered a minimally acceptable level, and these internal consistency levels also were found to be stable over time for each subscale, with the largest range of 0.06 noted for the Family Strain subscale. Consistent with the high a for the total mean scale, subscale correlations ranged from 0.44 to 0.65 at baseline, 0.44 to 0.65 at 100 days, and 0.39 to 0.72 at 180 days (P values < .001). Predictive validity was demonstrated by the moderately negative correlations of the baseline CTXD measure with MH at 100 days and 180 days (all r > -0.44). Patients with higher levels of distress before transplantation exhibited lower MH scores after transplantation. As with concurrent correlations supporting convergent and divergent validity, the correlations between the pretransplantation CTXD and the posttransplantation PF (r 5 -0.22 and -0.26, respectively) were lower than for MH. It is interesting to note that these correlations with MH and PF were different, although MH and PF were found to be significantly positively correlated with each other at each assessment. Finally, predictive validity also was supported by strong correlations of the baseline CTXD with CTXD at 100 days and 180 days. Finally, we evaluated the construct validity of the 6 subscales. The pattern of correlations for each subscale with MH and PF paralleled those of the CTXD total mean score. Within time points, all CTXD subscales correlated with MH at between -0.43 and -0.63. The highest correlations with MH consistently were found to be with Health Burden and Uncertainty, whereas the lowest were found with Finances. Within time points, the PF correlations with the CTXD subscales were generally lower, ranging from -0.20 to -0.35. The exceptions were for Health Burden, which ranged from -0.44 to -0.59, and Family Strain, which had an r of -0.43 at 100 days and an r of -0.48 at 180 days. The predictive validity of the subscales was generally supported with r values of >0.50 between baseline and follow-ups at 100 days and 180 days. The 2 minor exceptions were for Medical Demands (r > 0.45) and Health Burden from baseline to 100 days (r 5 0.48).
Construct Validity
DISCUSSION
In this large cohort of patients who underwent HCT and who were followed from before to 6 months after their transplantations, the CTXD demonstrated strong internal consistency reliability, as well as strong convergent, divergent, and predictive validity. Psychometric properties were found to be stable over time not only for the total mean score but also within the subscales. Distress on the CTXD total mean score declined on average by nearly one-half a SD by 180 days. Based on established definitions of clinically meaningful changes of one-half of an SD, 22, 23 this finding suggests that CTXD distress declines slowly but meaningfully over the 6 months after HCT. Among the subscales, patterns of change from before transplantation to 180 days after were descriptively more variable, with the least change observed in Health Burden over time and with the sharpest drop noted in Family Strain, which declined by greater than one-half of an SD from before transplantation to 180 days after.
The results of the current study support hypothesized levels of reliability and indicate that the CTXD has a consistent structure over time. The 6 subscales remained reliable, ranging from Cronbach a values of .90 to .77, with the reliabilities and SDs for each subscale remaining within a small range from before transplantation to 180 days after, even as the means declined. These reliabilities are within the range from acceptable to excellent without adding unnecessary redundancy to the measure. 24 This finding is interesting to note given that each subscale has only 3 or 4 items, and the most frequent response to items was "not at all." Thus, we believe the CTXD reduces patient response burden to as low a level as possible while preserving the ability to reliably assess multiple dimensions of the distress experience over time in patients undergoing HCT.
The reported correlations support the construct validity and, to some extent, the test-retest reliability of the CTXD. Ideally, test-retest reliability would be confirmed with assessments closer together in time and without the major events that occur during the 6 months of the HCT process. We tested predictive validity with the measures available from the parent study, and therefore we were restricted to the SF-36. It is interesting to note that the MH and PF results were consistent with the physical component and mental component summaries of the SF-36 (data not shown), even though for validity testing we considered the cleaner separation of the subscales using the MH and PF to be advantageous. Numerous aspects of the CTXD remain to be examined to determine the value of measuring cancerrelated distress as distinct from standardized global measures of mental health or the widely used single-item Distress Thermometer. To our knowledge, the Distress Thermometer has been examined in HCT populations in a few longitudinal studies. [25] [26] [27] Two studies that have considered factors contributing to HCT-related distress by examining the problem checklist categories that accompany the Distress Thermometer found results similar to those of the current study except with regard to family stress in that physical difficulties were most frequently checked as contributing to distress, followed by emotional concerns, practical concerns such as finances and work, and then family issues, with spiritual concerns receiving the lowest endorsement rates. 26, 27 We found high means for family strain, but otherwise similar ordering of the means for distress within the factors in the current study. In the development of the CTXD, we did not retain items measuring spiritual distress because we found low endorsement of spiritual distress in HCT recipients and those items did not contribute unique variance or reliability to the measure. 7 In addition, further research is needed to compare the sensitivity and specificity of the CTXD with those of standardized general population measures to ensure added value of the distress measure.
Although it is important that the CTXD predicts later values on similar measures and the CTXD itself, the predictive value of the CTXD will be enhanced if it also predicts later health outcomes of patients undergoing HCT such as psychosocial needs during and after HCT and health care needs such as hospitalization, disability, or costs of care. Now that the reliability and validity of the CTXD, including subscales, have been established, there is an opportunity to address these questions with prospective longitudinal studies.
In previous research, we established a cutpoint for clinically meaningfully elevated distress on the CTXD at a total mean score of >1. 1. 7 Using that criterion with these data, approximately 47% of the participants had elevated distress before transplantation, 35% had elevated distress at 100 days, and 32% had elevated distress at 180 days (data not shown). To the best of our knowledge, the value of the CTXD as a clinical tool remains to be demonstrated. The results presented herein do align with a meta-analysis of interview-based studies identifying the prevalence of depression, anxiety, and adjustment disorder, which found that overall 30% to 40% of patients with cancer had 1 psychiatric mood disorders. 28 Given the intensity of HCT, we would expect rates to be at least that high. Future research will examine whether the CTXD can be useful for identifying those patients in need of an intervention for their distress.
Other topics remain to be investigated with the CTXD, including whether it has value for assessing distress in patients with other cancer diagnoses or treatments. Although numerous items were tested that could be specific to HCT, such as distress related to chronic graftversus-host disease, none of those items were retained in the final CTXD factor analyses during development. 7 Thus, the items in the CTXD are not specific to HCT, and the measure could be relevant to other cancer diagnostic groups or treatments. Psychometric testing is needed to establish its value with these other populations. Furthermore, the question of whether the measure provides useful identification of those individuals at higher risk of poor outcomes during or after HCT remains to be tested, as does its sensitivity to detecting treatment differences. The CTXD has been translated into German with similar results, 29 but studies in other languages and with greater cultural diversity are needed.
Several strengths and limitations need to be noted. To the best of our knowledge, the current study is the first published longitudinal analysis of the psychometric properties of the CTXD. The sample is a large cohort from 21 transplantation centers, suggesting that it may be representative of the broader HCT population. Limitations include the possibility of biases in the study enrollment because the parent protocol was an RCT that may have been of more interest to some HCT recipients than others. The participants were largely well educated, and the majority were of middle to higher income status. Normative data regarding the CTXD over time in a cohort of patients undergoing HCT who are not enrolled on a clinical trial would be valuable. The measures collected during this clinical trial do not provide a "gold-standard" measure of cancer-related distress from which to evaluate sensitivity, specificity, and clinically meaningful cutpoints. In addition, because the study only followed patients for 6 months, the psychometric stability of the CTXD as a multidimensional measure of distress for long-term survivors is unknown.
The CTXD, as tested in this secondary analysis from an RCT data set, demonstrated strong reliability and validity. With further testing relative to established measures such as clinical diagnostic interviews, the CTXD with its subscales could be useful for screening distress and identifying the types of interventions patients require during and after HCT. This evidence supports the value of the CTXD as a research or clinical tool for assessing not only overall distress but also the domains contributing to distress in patients undergoing HCT over the first 6 months after treatment.
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